Tayshia said all 33 patients cleared acute safety monitoring, with no severe treatment-related serious adverse events or dose-limiting toxicities as of the November 2026 cutoff. Six-month interim data and FDA pathway feedback are expected in the first half of 2027.
TSHA · Taysha Gene Therapies, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Taysha Gene Therapies completed TSHA-102’s BLA-enabling PPQ campaign, meeting predefined specifications and comparability criteria; topline data from the REVEAL pivotal 6-month interim analysis and FDA feedback on the BLA submission pathway are expected in the first half of 2027.
Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.